Form D · Pharmaceuticals
Squarex Pharmaceutical Corp
Saint Paul, MN · CIK 0001864607
Offering snapshot reported Nov 22, 2022 · SEC filing
- Reported sold
- $25K Offering amount: $2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Oct 24, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 22, 2022 | Initial | $25,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-465666
Convertible Promissory Note
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| None | None |
Source: Form D, filed Nov 22, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Arkadiusz Dudek | Director |
| Hugh Mc Tavish | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1000 Westgate Drive, Suite 1010
Saint Paul, MN, 55114
Saint Paul, MN, 55114